Skip to content

Agios Pharmaceuticals

US · AGIO #2841 by market cap Listed 1970
27.60 -1.16 -4.03%
Periodic snapshot; not a real-time feed. · 2026-11-20 19:30

Price chart

After-hours 27.60 0.00%
44.0126.5127.602026-05-262026-11-20
MA5MA10MA20MA60
— MA5 — MA10 — MA20 — MA60
Reader sentiment Are you bullish or bearish on AGIO?

Anonymous reader poll. Unscientific, not investment advice.

✦ StockVane Quant Insights how this is computed

Quant Sentiment Neutral
  • Recent price momentum is -2.8% on average (3-month/1-year).
  • Main-fund capital flow has been a net inflow over the last 45 sessions.
  • Short interest has fallen to 10.9% of float.
  • Analyst tilt is Buy.
Quant Technical Outlook Bearish
  • Price is below its 20-day average and below its 60-day average.
  • The 20-day average is below the 60-day average, a short-term downtrend.
Quant Rating, last 30 days D → E

Computed by a StockVane algorithm from historical price, valuation and analyst data - not a person, not a forecast guarantee, and not investment advice.

Factor grades

Ranked against 2848 U.S. stocks StockVane covers.

Last computed: 2026-11-22 02:27 UTC

Data coverage: 5 of 6 factors. Missing data is not a zero score.

Overall B-

The radar needs all six factors. Available grades are shown below.

Valuation N/A

How expensive the stock is versus earnings, sales and its own 5-year history.

Not enough data to grade this factor.

Growth B

How fast revenue, profit and free cash flow are compounding.

Revenue CAGR (3Y) 56.0% Better than 96%
Net income CAGR (3Y) -25.1% Better than 14%
Profitability D+

How much profit the business keeps from each dollar of sales and capital.

Gross margin 88.3% Better than 96%
Operating margin -873.9% Better than 3%
Net margin -764.0% Better than 3%
Return on equity -30.2% Better than 13%
Return on invested capital -33.1% Better than 9%
Momentum B-

Recent price strength, skipping the latest month to avoid short-term noise.

3-month return -16.6% Better than 37%
6-month return -1.9% Better than 52%
12-month return (ex latest month) 46.6% Better than 82%
Distance below 52-week high 37.4% Better than 31%
Financial Health B+

Balance-sheet strength: leverage, liquidity and interest coverage.

Current ratio 11.5x Better than 95%
Debt to assets 3.1% Better than 84%
Interest coverage -17.4x Better than 10%
Analyst View B

What the Street thinks: share of Buy ratings and upside to the average target.

Analysts rating Buy 66.7% Better than 41%
Upside to average target 65.9% Better than 74%

Grades are relative rankings, not forecasts: A+ is the top 5% of the covered stocks on a factor, F the bottom 3%. Valuation is not adjusted for sector. Background recomputation is scheduled every 6 hours; actual computation time is shown above, and source datasets have different reporting dates. Not investment advice or tailored to your financial situation.

Performance

1W -12.63%
1M -24.67%
3M -17.93%
6M -3.16%
YTD +1.40%
1Y +12.33%
3Y +28.37%
5Y -27.79%

Key statistics

Price & volume

Prev close
28.76
Open
28.01
Day range
27.43 - 29.14
Avg price
27.92
Volume
776.20K
Turnover
21.67M
Amplitude
5.95%
52-week range
24.16 - 44.09

Valuation

P/E
-3.88
P/E (TTM)
-4.37
P/B
1.69
EPS
-7.12
Net profit
-425.84M
Net assets
979.32M

Share structure

Market cap
1.65B
Float cap
1.36B
Shares out
59.81M
Float shares
49.32M

Dividend & listing

Dividend (TTM)
0.00
Listing date
1970-01-01
52-week range 17% of range
24.16 44.09

37.4% below the 52-week high

Trading activity

Net capital flow main funds, last 45 sessions

+10.36M net over the window

Short interest

Shares short
6.52M
As of
2026-10-30

Frequently asked questions

What is the current stock price of Agios Pharmaceuticals (AGIO)?

Agios Pharmaceuticals last traded at 27.60. This page shows a periodic quote snapshot. Check the displayed quote time.

What is Agios Pharmaceuticals's market cap?

About 1.65B.

What is the P/E ratio of Agios Pharmaceuticals?

The trailing twelve-month P/E is -4.37. The Valuation tab shows it against the stock's own five-year range.

Does Agios Pharmaceuticals pay a dividend?

Agios Pharmaceuticals does not currently pay a regular dividend.

Is Agios Pharmaceuticals a buy according to analysts?

The consensus of 6 analysts is a Buy rating, with an average 12-month price target of 45.80, which implies 65.9% upside from the current price. This is not investment advice.

What is Agios Pharmaceuticals's StockVane Quant Rating?

The StockVane Momentum strategy currently rates Agios Pharmaceuticals a D (Sell). Below its 200-day average or in the bottom third on momentum — the strategy is out of it. Not investment advice.

Quote time 2026-11-20 19:30:06 · For reference only, not investment advice and not tailored to your situation.

Agios Pharmaceuticals discussion 0 comments

Add a comment